Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Toy Industry Braces For Bankruptcies Under Tariffs No Photo Available

Hilary Russ

After Joann Cartiglia started designing dolls from the basement of her home two decades ago, business took off and she began selling t... (more story)

Catching Up With New Bankruptcy Case Action No Photo Available

Emlyn Cameron

Drugstore chain Rite Aid Corp. reentered bankruptcy with over $1 billion in debt less than a year after its earlier reorganization pla... (more story)

Meet The Attorneys Guiding Balkan Express' Ch.11 No Photo Available

Yun Park

A team of lawyers from Bonds Ellis Eppich Schafer Jones LLP is leading the bankruptcy case of Texas-based transportation company Balka... (more story)